Equity Brief · Healthcare2026-05-20
AMGN·Healthcare

Amgen Inc

I · Análisis con IA

En breve

Amgen discovers, develops, manufactures, and delivers prescription medicines for serious illnesses including rheumatoid arthritis (Enbrel), high cholesterol (Repatha), osteoporosis (Prolia, Evenity), cancer (Blincyto, Kyprolis, Vectibix), and rare diseases like thyroid eye disease (Tepezza) [Yahoo Finance]. The company sells through doctors' offices, hospitals, dialysis centers, and pharmacies, primarily via pharmaceutical wholesalers [Yahoo Finance].

Amgen is the world's largest independent biotech company, developing and selling medicines for cancer, autoimmune diseases, osteoporosis, and rare conditions [Yahoo Finance]. The company generates $36.7B in annual revenue with strong margins, but faces serious safety concerns around its drug Tavneos, which has been linked to 20 deaths and 22 liver injuries in Japan [Seeking Alpha]. Recent leadership changes include the retirement of CFO Peter Griffith, who will be replaced by returning veteran Thomas Dittrich [Yahoo Finance].

Amgen is financially healthy with strong cash generation and reasonable leverage, earning a 7.4/10 health score [Yahoo Finance].

En breve AI analysisConfianza 8/10

Puntuación Sentinellis

7.4/10

Financially healthy

Capitalización bursátil

$178.6B

Ingresos (12 meses)

$36.7B

II · Noticias recientes

Qué movió el precio

6 stories · ranked by relevance

  • macro2026-05-19

    AMGEN ANNOUNCES RETIREMENT OF CHIEF FINANCIAL OFFICER PETER GRIFFITH

    Yahoo Finance

  • macro2026-05-18

    Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism

    Yahoo Finance

  • macro2026-05-18

    Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed

    Yahoo Finance

  • macro2026-05-18

    Amgen Japanese Partner Urges Caution On Tavneos Use

    Yahoo Finance

  • macro2026-05-15

    Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains

    Simply Wall St

  • macro2026-05-15

    Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

    Zacks

Premium · gratis con cualquier cuenta

Tavneos faces serious safety scrutiny in Japan after being linked to 20 deaths and 22 liver injuries, which could lead to restricted use, regulatory action, or lawsuits in other markets where Amgen sells the drug [Seeking Alpha]

1 de 4 riesgos en este informe

Riesgos

4

Oportunidades

5

Señales de alerta

3

Dirección

10

21 hallazgos más en el informe completo — gratis con cualquier cuenta.

Desbloquea el análisis completo de Amgen Inc

Crea una cuenta gratuita para acceder al informe completo generado con IA, con fuentes citadas en el texto.

  • 4 riesgos, 5 oportunidades y 3 señales de alerta — cada uno con su fuente
  • Más de 100 métricas financieras con gráficos y comparativas
  • Resúmenes completos de noticias con enlaces a las fuentes
  • Equipo directivo y remuneración
  • Exportación a PDF para leer sin conexión
Desbloquea los 12 hallazgos3 informes gratis · sin tarjeta

III · Empresas similares

También te puede interesar

Same sector · Healthcare or comparable health

¿La añades a tu lista?

Read three companies free. Sin tarjeta.

Consigue 3 informes gratis